TSE:HEXO

HEXO Competitors

C$7.46
+0.12 (+1.63 %)
(As of 04/14/2021 09:33 AM ET)
Add
Compare
Today's Range
C$7.40
Now: C$7.46
C$7.50
50-Day Range
C$7.34
MA: C$8.61
C$9.80
52-Week Range
C$2.24
Now: C$7.46
C$14.00
Volume42,478 shs
Average Volume2.46 million shs
Market CapitalizationC$913.00 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

HEXO (TSE:HEXO) Vs. LEAF, ACB, OGI, GUD, HLS, and FIRE

Should you be buying HEXO stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to HEXO, including Leaf Mobile (LEAF), Aurora Cannabis (ACB), OrganiGram (OGI), Knight Therapeutics (GUD), HLS Therapeutics (HLS), and The Supreme Cannabis (FIRE).

HEXO (TSE:HEXO) and Leaf Mobile (TSE:LEAF) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for HEXO and Leaf Mobile, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HEXO02012.67
Leaf Mobile00103.00

HEXO currently has a consensus price target of C$1.76, indicating a potential downside of 76.41%. Leaf Mobile has a consensus price target of C$0.75, indicating a potential upside of 108.33%. Given Leaf Mobile's stronger consensus rating and higher probable upside, analysts plainly believe Leaf Mobile is more favorable than HEXO.

Valuation and Earnings

This table compares HEXO and Leaf Mobile's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HEXOC$111.62 million8.18C$-247,219,720.00C($2.02)-3.69
Leaf MobileC$19.24 million14.30C$-4,586,262.00C($0.01)-60.00

Leaf Mobile has lower revenue, but higher earnings than HEXO. Leaf Mobile is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares HEXO and Leaf Mobile's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HEXON/AN/AN/A
Leaf MobileN/AN/AN/A

Summary

Leaf Mobile beats HEXO on 6 of the 9 factors compared between the two stocks.

Aurora Cannabis (TSE:ACB) and HEXO (TSE:HEXO) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.

Earnings and Valuation

This table compares Aurora Cannabis and HEXO's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora CannabisC$285.54 million7.10C$-3,829,329,160.00C($19.34)-0.53
HEXOC$111.62 million8.18C$-247,219,720.00C($2.02)-3.69

HEXO has lower revenue, but higher earnings than Aurora Cannabis. HEXO is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aurora Cannabis and HEXO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora CannabisN/AN/AN/A
HEXON/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Aurora Cannabis and HEXO, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis35001.63
HEXO02012.67

Aurora Cannabis presently has a consensus price target of C$11.91, indicating a potential upside of 16.35%. HEXO has a consensus price target of C$1.76, indicating a potential downside of 76.41%. Given Aurora Cannabis' higher possible upside, analysts plainly believe Aurora Cannabis is more favorable than HEXO.

Summary

HEXO beats Aurora Cannabis on 5 of the 8 factors compared between the two stocks.

HEXO (TSE:HEXO) and OrganiGram (TSE:OGI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.

Profitability

This table compares HEXO and OrganiGram's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HEXON/AN/AN/A
OrganiGramN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for HEXO and OrganiGram, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HEXO02012.67
OrganiGram06202.25

HEXO currently has a consensus target price of C$1.76, indicating a potential downside of 76.41%. OrganiGram has a consensus target price of C$4.13, indicating a potential upside of 18.77%. Given OrganiGram's higher possible upside, analysts clearly believe OrganiGram is more favorable than HEXO.

Earnings and Valuation

This table compares HEXO and OrganiGram's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HEXOC$111.62 million8.18C$-247,219,720.00C($2.02)-3.69
OrganiGramC$80.97 million12.82C$-274,636,674.00C($0.92)-3.78

HEXO has higher revenue and earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.

Summary

HEXO beats OrganiGram on 5 of the 9 factors compared between the two stocks.

Knight Therapeutics (TSE:GUD) and HEXO (TSE:HEXO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.

Earnings & Valuation

This table compares Knight Therapeutics and HEXO's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$199.52 million3.40C$41.08 millionC$0.3216.52
HEXOC$111.62 million8.18C$-247,219,720.00C($2.02)-3.69

Knight Therapeutics has higher revenue and earnings than HEXO. HEXO is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Knight Therapeutics and HEXO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Knight Therapeutics00303.00
HEXO02012.67

Knight Therapeutics currently has a consensus target price of C$7.42, indicating a potential upside of 40.73%. HEXO has a consensus target price of C$1.76, indicating a potential downside of 76.41%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Knight Therapeutics is more favorable than HEXO.

Profitability

This table compares Knight Therapeutics and HEXO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Knight TherapeuticsN/AN/AN/A
HEXON/AN/AN/A

Summary

Knight Therapeutics beats HEXO on 7 of the 9 factors compared between the two stocks.

HLS Therapeutics (TSE:HLS) and HEXO (TSE:HEXO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares HLS Therapeutics and HEXO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HLS TherapeuticsN/AN/AN/A
HEXON/AN/AN/A

Valuation & Earnings

This table compares HLS Therapeutics and HEXO's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HLS TherapeuticsC$56.11 million10.72C$-19,284,132.00C($0.61)-31.20
HEXOC$111.62 million8.18C$-247,219,720.00C($2.02)-3.69

HLS Therapeutics has higher earnings, but lower revenue than HEXO. HLS Therapeutics is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for HLS Therapeutics and HEXO, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HLS Therapeutics00213.33
HEXO02012.67

HLS Therapeutics currently has a consensus price target of C$30.50, suggesting a potential upside of 61.29%. HEXO has a consensus price target of C$1.76, suggesting a potential downside of 76.41%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe HLS Therapeutics is more favorable than HEXO.

Summary

HLS Therapeutics beats HEXO on 6 of the 8 factors compared between the two stocks.

HEXO (TSE:HEXO) and The Supreme Cannabis (TSE:FIRE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for HEXO and The Supreme Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HEXO02012.67
The Supreme Cannabis0000N/A

HEXO currently has a consensus price target of C$1.76, suggesting a potential downside of 76.41%. The Supreme Cannabis has a consensus price target of C$0.35, suggesting a potential downside of 9.09%. Given The Supreme Cannabis' higher probable upside, analysts plainly believe The Supreme Cannabis is more favorable than HEXO.

Profitability

This table compares HEXO and The Supreme Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HEXON/AN/AN/A
The Supreme CannabisN/AN/AN/A

Valuation and Earnings

This table compares HEXO and The Supreme Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HEXOC$111.62 million8.18C$-247,219,720.00C($2.02)-3.69
The Supreme CannabisC$49.44 million5.72C$-153,549,792.00C($0.21)-1.84

The Supreme Cannabis has lower revenue, but higher earnings than HEXO. HEXO is trading at a lower price-to-earnings ratio than The Supreme Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

The Supreme Cannabis beats HEXO on 4 of the 7 factors compared between the two stocks.


HEXO Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Leaf Mobile logo
LEAF
Leaf Mobile
1.2$0.36+2.8%C$2.47 billionC$19.24 million-60.00Gap Down
Aurora Cannabis logo
ACB
Aurora Cannabis
1.0$10.24+1.4%C$2.03 billionC$285.54 million-0.53
OrganiGram logo
OGI
OrganiGram
1.3$3.48+0.6%C$1.09 billionC$80.97 million-3.78Analyst Report
News Coverage
Knight Therapeutics logo
GUD
Knight Therapeutics
1.7$5.27+0.6%C$681.16 millionC$199.52 million16.52
HLS Therapeutics logo
HLS
HLS Therapeutics
1.4$18.91+0.3%C$601.75 millionC$56.11 million-31.20
FIRE
The Supreme Cannabis
1.0$0.39+1.3%C$282.86 millionC$49.44 million-1.84
ICC
ICC Labs
0.5$1.62+6.2%C$228.24 millionC$533,684.0095.29Gap Down
The Green Organic Dutchman logo
TGOD
The Green Organic Dutchman
0.8$0.32+1.6%C$166.07 millionC$21.50 million-0.64
EPI
ESSA Pharma
0.6$8.20+6.7%C$145.78 millionN/A-8.27
WMD
WeedMD
1.3$0.32+1.6%C$95.35 millionC$27.21 million-3.64
NINE
Delta 9 Cannabis
0.8$1.03+2.9%C$89.36 millionC$12.87 million19.07Gap Down
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.05+10.0%C$84.57 millionC$1.09 million-1.32Gap Up
FLWR
The Flowr
1.0$0.32+1.6%C$70.01 millionC$5.96 million-0.82
RX
BioSyent
0.8$7.60+1.3%C$64.81 millionC$22.33 million26.21News Coverage
MDP
Medexus Pharmaceuticals
0.6$7.40+0.3%C$38.66 millionC$108.29 million-4.09
VIR
Viridium Pacific Group
0.7$0.38+5.3%C$37.54 millionC$1.09 million-2.97Gap Down
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
0.6$0.29+7.0%C$36.73 millionN/A-2.61Gap Up
Cipher Pharmaceuticals logo
CPH
Cipher Pharmaceuticals
0.7$1.35+0.0%C$36.41 millionC$21.61 million8.13
IN
InMed Pharmaceuticals
0.6$4.26+3.3%C$33.01 millionN/A-2.95Gap Down
NDVA
Indiva
1.3$0.47+3.2%C$27.54 millionC$7.92 million-3.67News Coverage
Gap Up
Harvest One Cannabis logo
HVT
Harvest One Cannabis
0.4$0.12+4.3%C$21.51 millionC$8.50 million-0.32Gap Down
EVE
Eve & Co Incorporated
1.0$0.35+1.4%C$21.32 millionC$2.84 million-1.10
SUGR
SugarBud Craft Growers
0.7$0.05+0.0%C$11.81 millionC$66,906.00-0.03News Coverage
Gap Down
NU
NeutriSci International
0.5$0.20+5.1%C$8.65 millionC$69,626.00-15.00
AQS
Aequus Pharmaceuticals
0.9$0.23+0.0%C$6.03 millionC$2.28 million-10.45Gap Up
LBL
Lattice Biologics
0.5$0.05+10.0%C$4.67 millionC$2.24 million-2.63Gap Up
THCX
(THCX.V)
0.6$5.30+6.2%C$0.00N/A0.00High Trading Volume
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Down
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Down
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00Gap Down
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
Gap Down
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5N/AN/AC$0.00N/A0.00News Coverage
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.